Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol

Satoshi Akagi, Hiromi Matsubara, Katsumasa Miyaji, Etsuko Ikeda, Kazuhiro Dan, Naoto Tokunaga, Kenichi Hisamatsu, Mitsuru Munemasa, Yoshihisa Fujimoto, Tohru Ohe

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p<0.05), There was a significant decrease from the baseline value for systolic pulmonary artery pressure (80.1 ± 19.3 to 66.8 ± 16.5 mmHg, p<0.05). These effects were maintained for I year without progression of PAH in 6 patients whose condition had been stabilized at baseline. Conclusions The additional use of bosentan for IPAH patients whose condition has been stabilized by high-dose EPO is safe and effective.

Original languageEnglish
Pages (from-to)1142-1146
Number of pages5
JournalCirculation Journal
Volume72
Issue number7
DOIs
Publication statusPublished - 2008

Keywords

  • Bosentan
  • Combination therapy
  • Epoprostenol
  • Idiopathic pulmonary arterial hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol'. Together they form a unique fingerprint.

  • Cite this

    Akagi, S., Matsubara, H., Miyaji, K., Ikeda, E., Dan, K., Tokunaga, N., Hisamatsu, K., Munemasa, M., Fujimoto, Y., & Ohe, T. (2008). Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circulation Journal, 72(7), 1142-1146. https://doi.org/10.1253/circj.72.1142